Ironwood pharmaceuticals announces receipt of nasdaq non-compliance notification regarding late 2024 form 10-k filing

Boston--(business wire)--ironwood pharmaceuticals, inc. (the “company”) (nasdaq: irwd), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (gi) and rare diseases, today announced that it received a notification letter (the “notice”) on march 21, 2025 from the listing qualifications department of the nasdaq stock market llc (“nasdaq”) indicating that, as a result of the company's delay in filing its annual report on form 10-k fo.
NDAQ Ratings Summary
NDAQ Quant Ranking